Drugs becoming eligible for first Paragraph IV ANDA filing in 2030
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46792 | ACROTECH | NA |
Mar, 2028
(1 year, 3 months from now) | |
| US10588893 | ACROTECH | Ointment Containing An Oxazole Compound |
Dec, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2031 |
Drugs and Companies using DIFAMILAST ingredient
NCE-1 date: 12 February, 2030
Market Authorisation Date: 12 February, 2026
Treatment: Method of treating atopic dermatitis
Dosage: OINTMENT
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10137209 | BAYER | Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging |
May, 2036
(9 years from now) | |
| US12478696 | BAYER | Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging |
May, 2036
(9 years from now) | |
| US11491245 | BAYER | Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging |
May, 2036
(9 years from now) | |
| US10722601 | BAYER | Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging |
May, 2036
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12303573 | BAYER | Formulation Of Contrast Media And Process Of Preparation Thereof |
Nov, 2039
(13 years from now) | |
| US11944690 | BAYER | Formulation Of Contrast Media And Process Of Preparation Thereof |
May, 2040
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 12, 2031 |
Drugs and Companies using GADOQUATRANE ingredient
NCE-1 date: 12 June, 2030
Market Authorisation Date: 12 June, 2026
Treatment: Method of magnetic resonance imaging to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine, and associated tissues) and the body (head and neck, thorax,...
Dosage: SOLUTION
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10710980 | MIRUM | Aminopyridine Derivatives And Their Use As Selective Alk-2 Inhibitors |
Jul, 2037
(10 years from now) | |
| US12466808 | MIRUM | Aminopyridine Derivatives And Their Use As Selective Alk-2 Inhibitors |
May, 2039
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10947218 | MIRUM | Aminopyridine Derivatives And Their Use As Selective Alk-2 Inhibitors |
Jul, 2037
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2031 |
Drugs and Companies using ZILURGISERTIB FUMARATE ingredient
NCE-1 date: 25 September, 2030
Market Authorisation Date: 25 September, 2026
Treatment: Reduce the volume of total new heterotopic ossification (ho) in adults and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (fop)
Dosage: TABLET
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9353081 | ASTRAZENECA | Bicyclic Dihydroquinoline-2-One Derivatives |
Feb, 2033
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 15, 2031 |
Drugs and Companies using BAXDROSTAT ingredient
NCE-1 date: 15 May, 2030
Market Authorisation Date: 15 May, 2026
Treatment: NA
Dosage: TABLET
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11420968 | BEONE MEDICINES | Bcl-2 Inhibitors |
Apr, 2039
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2031 |
Drugs and Companies using SONROTOCLAX ingredient
NCE-1 date: 13 May, 2030
Market Authorisation Date: 13 May, 2026
Treatment: NA
Dosage: TABLET
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10570453 | VANDA | Method Of Predicting A Predisposition To Qt Prolongation |
Mar, 2028
(1 year, 4 months from now) | |
| US9157121 | VANDA | Method of treatment based on polymorphisms of the KCNQ1 gene |
Apr, 2030
(3 years from now) | |
| US10563259 | VANDA | Method Of Treatment Based On Polymorphisms Of The Kcnq1 Gene |
Jul, 2030
(3 years from now) | |
| US12606869 | VANDA | Methods For The Administration Of Iloperidone |
Sep, 2030
(3 years from now) | |
| US8999638 | VANDA | Method of treatment based on polymorphisms of the KCNQ1 gene |
Oct, 2030
(3 years from now) | |
| US9074255 | VANDA | Method of predicting a predisposition to QT prolongation |
Dec, 2030
(4 years from now) | |
| US9072742 | VANDA | Method of predicting a predisposition to QT prolongation |
Jan, 2031
(4 years from now) | |
| US9074256 | VANDA | Method of predicting a predisposition to QT prolongation |
Feb, 2031
(4 years from now) | |
| US9074254 | VANDA | Method of predicting a predisposition to QT prolongation |
Dec, 2031
(5 years from now) | |
| US12478619 | VANDA | Method Of Treatment With Milsaperidone |
May, 2044
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 20, 2031 |
Drugs and Companies using MILSAPERIDONE ingredient
NCE-1 date: 20 February, 2030
Market Authorisation Date: 20 February, 2026
Treatment: Method for acute treatment of manic or mixed episodes associated with bipolar i disorder in adults by administering milsaperidone to a patient by lowering the dose after determining that the patient h...
Dosage: TABLET
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9517988 | HAISCO | Phenol Derivative And Preparation Method And Use In Medicine Thereof |
May, 2034
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10729666 | HAISCO | Use Of Gabaa Receptor Reinforcing Agent In Preparation Of Sedative And Anesthetic Medicament |
May, 2034
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2031 |
Drugs and Companies using CIPEPOFOL ingredient
NCE-1 date: 27 August, 2030
Market Authorisation Date: 27 August, 2026
Treatment: Inducing general anesthesia in adults undergoing surgery
Dosage: EMULSION
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12611383 | RARE THYROID | NA |
Jul, 2045
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2031 |
Drugs and Companies using TIRATRICOL ingredient
NCE-1 date: 28 September, 2030
Market Authorisation Date: 28 September, 2026
Treatment: Treatment of peripheral thyrotoxicosis in adults and pediatric patients with mct8 deficiency (allan-herndon-dudley syndrome) by administering tiratricol
Dosage: TABLET, FOR SUSPENSION
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10131663 | ASTRAZENECA | Chemical Compounds |
Oct, 2037
(10 years from now) | |
| US10590130 | ASTRAZENECA | Chemical Compounds |
Oct, 2037
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10961241 | ASTRAZENECA | Chemical Compounds |
Oct, 2037
(10 years from now) | |
| US12077530 | ASTRAZENECA | Chemical Compounds |
Oct, 2037
(10 years from now) | |
| US12364689 | ASTRAZENECA | Dosage Regimen For The Treatment Of Cancer |
Sep, 2041
(14 years from now) | |
| US12453729 | ASTRAZENECA | Pharmaceutical Formulations |
Oct, 2041
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2031 |
Drugs and Companies using CAMIZESTRANT ingredient
NCE-1 date: 04 September, 2030
Market Authorisation Date: 04 September, 2026
Treatment: Treatment with a cdk4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) of hr-pos., her2-neg. locally advanced or metastatic breast cancer upon detection of esr1 mutation during aromatase inhibito...
Dosage: TABLET
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE50455 | ELI LILLY | NA |
Sep, 2037
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 01, 2031 |
Drugs and Companies using ORFORGLIPRON CALCIUM ingredient
NCE-1 date: 01 April, 2030
Market Authorisation Date: 01 April, 2026
Treatment: Treatment to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight with at least one weight-related comorbid condition by administering an effective am...
Dosage: TABLET